Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Phase Ib trial of R-CHOP plus iberdomide or CC-99282 in aggressive B-cell lymphoma

Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, describes an ongoing Phase Ib trial-in-progress assessing two cereblon-modulating agents, iberdomide and CC-99282, in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), for the treatment of previously untreated aggressive B-cell lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

We’re presenting a Phase Ib study looking at R-CHOP in combination with two very cool drugs, cereblon modifiers called CC-220, or iberdomide, or CC-99282. So, the patients are not getting both of those drugs. Instead, half the patients are getting 99282, half of them getting iberdomide, and all patients are getting R-CHOP. These cereblon-targeting drugs are the new version of lenalidomide and they have incredible promise...

We’re presenting a Phase Ib study looking at R-CHOP in combination with two very cool drugs, cereblon modifiers called CC-220, or iberdomide, or CC-99282. So, the patients are not getting both of those drugs. Instead, half the patients are getting 99282, half of them getting iberdomide, and all patients are getting R-CHOP. These cereblon-targeting drugs are the new version of lenalidomide and they have incredible promise. In single-agent trials in the past, they’ve shown very good response rates, and in combination with R-CHOP thus far, we’re seeing some impressive results. At this ASH Trials-in-Progress poster, we’re not yet presenting any data, but the study is open and accruing very well, and we’re hoping to see future studies combining cereblon agents and R-CHOP in the frontline setting.

Read more...

Disclosures

Novartis: Consultancy, Research Funding; MorphoSys/Incyte Corporation: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Calithera: Consultancy, Research Funding; Iksuda: Consultancy; ADC Therapeutics: Consultancy, Research Funding; MonteRosa: Consultancy; AstraZeneca: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Merck: Consultancy; Abbvie/GenMab: Consultancy; SeaGen: Consultancy.